Navigation Links
Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
Date:5/17/2013

SAN DIEGO, May 17, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the UBS Global Healthcare Conference in New York. The presentation is scheduled for Wednesday, May 22nd at 11 a.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2019)... (PRWEB) , ... August 16, 2019 , ... ... aminopeptidase inhibitor (BAPAI) that could potentially treat treatment-resistant hypertension by acting in the ... are around 150 million people worldwide that are affected by treatment-resistant hypertension, resulting ...
(Date:8/16/2019)... ... August 16, 2019 , ... ... since 2005, announced it has successfully completed enrollment of 690 patients for a ... a dose ranging, multicenter, randomized, double-blind, placebo-controlled, home use, parallel group clinical trial ...
(Date:8/14/2019)... ... August 14, 2019 , ... Bach Pharma, Inc., a ... its drug platform GVT (Monosodium Luminol), created to treat and cure multiple neurodegenerative ... data from multiple animal studies have proven that GVT has the potential to ...
Breaking Medicine Technology:
(Date:8/14/2019)... , ... August 14, 2019 , ... Teguar Corporation has ... in America. This list has long-been established as a mark of success for some ... Dell, and Oracle. Teguar made the list in 2015, 2016 and 2017. This year, ...
(Date:8/14/2019)... ... August 14, 2019 , ... ... Team Assistant support, has earned a place on the Inc. magazine 500/5000 list ... inclusion marks nearly a decade of ScribeAmerica’s recognition as one of the fastest ...
(Date:8/14/2019)... ... August 13, 2019 , ... New Hampshire-based Vera Roasting Company , makers ... expansion of its line of CBD-infused coffees with the release of a new higher-dosage ... bag. , “We are excited to expand our CBD-infused product lines to include ...
(Date:8/14/2019)... (PRWEB) , ... August 13, 2019 , ... In a ... the purpose of doubt in your belief systems. , “Doubt can obliterate your old ... on the path to examining them to expand your understanding and your awareness. Trust ...
(Date:8/14/2019)... ... August 14, 2019 , ... While it is commonly ... their food and beverage choices can help them manage and, in some cases, reverse ... finds that about a quarter of U.S. adults are trying to manage a health ...
Breaking Medicine News(10 mins):